<code id='5567A2240D'></code><style id='5567A2240D'></style>
    • <acronym id='5567A2240D'></acronym>
      <center id='5567A2240D'><center id='5567A2240D'><tfoot id='5567A2240D'></tfoot></center><abbr id='5567A2240D'><dir id='5567A2240D'><tfoot id='5567A2240D'></tfoot><noframes id='5567A2240D'>

    • <optgroup id='5567A2240D'><strike id='5567A2240D'><sup id='5567A2240D'></sup></strike><code id='5567A2240D'></code></optgroup>
        1. <b id='5567A2240D'><label id='5567A2240D'><select id='5567A2240D'><dt id='5567A2240D'><span id='5567A2240D'></span></dt></select></label></b><u id='5567A2240D'></u>
          <i id='5567A2240D'><strike id='5567A2240D'><tt id='5567A2240D'><pre id='5567A2240D'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:Wikipedia    Page View:71534
          Adobe

          The Biden administration moved Wednesday to force insurance companies to give specific reasons for denying coverage, and to speed up the pre-approval process in general.

          The new rule applies to health insurance companies that offer Medicare, Medicaid, Children’s Health Insurance Program, and Obamacare plans. It concerns so-called prior authorization requests, and will require insurers to return urgent requests within 72 hours and non-urgent requests within seven days.

          advertisement

          The changes are a win for patients seeking care, but also for health care providers like hospitals and physicians. Executives from California-based Sutter Health, Massachusetts General Brigham, and others repeatedly cited the rise in insurer denials since the pandemic at last week’s J.P. Morgan Healthcare conference.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          AstraZeneca, Daiichi breast cancer treatment succeeds in trial
          AstraZeneca, Daiichi breast cancer treatment succeeds in trial

          AlastairGrant/APLONDON—AstraZenecasaidFridayanexperimentaldrugtampeddowntheprogressionofacertaintype

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Second xenotransplant done with gene

          TheUniversityofMarylandteampreparesthepigheartfortransplant.CourtesyUniversityofMarylandSchoolofMedi